BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,575 | -17.2% | 1,446 | 0.0% | 0.05% | -10.7% |
| Q2 2023 | $65,884 | +12.3% | 1,446 | 0.0% | 0.06% | -6.7% |
| Q1 2023 | $58,653 | -93.1% | 1,446 | -91.4% | 0.06% | -92.2% |
| Q4 2022 | $853,289 | -46.1% | 16,741 | -43.0% | 0.77% | -48.5% |
| Q3 2022 | $1,582,000 | -13.6% | 29,369 | +3.1% | 1.49% | -5.8% |
| Q2 2022 | $1,832,000 | -15.3% | 28,477 | +2.1% | 1.58% | +6.7% |
| Q1 2022 | $2,162,000 | +171.9% | 27,887 | +201.1% | 1.48% | +205.3% |
| Q4 2021 | $795,000 | -50.4% | 9,262 | -53.6% | 0.49% | -52.6% |
| Q3 2021 | $1,604,000 | -3.0% | 19,948 | -2.9% | 1.02% | -5.4% |
| Q2 2021 | $1,654,000 | -3.9% | 20,550 | +97.4% | 1.08% | -8.8% |
| Q1 2021 | $1,721,000 | +31.9% | 10,411 | -36.0% | 1.19% | +20.5% |
| Q4 2020 | $1,305,000 | +97.4% | 16,269 | +97.9% | 0.99% | +69.6% |
| Q3 2020 | $661,000 | +26.9% | 8,220 | +35.8% | 0.58% | +13.7% |
| Q2 2020 | $521,000 | -5.6% | 6,055 | -4.1% | 0.51% | -22.3% |
| Q3 2019 | $552,000 | +6.8% | 6,315 | 0.0% | 0.66% | +12.1% |
| Q2 2019 | $517,000 | +0.8% | 6,315 | 0.0% | 0.59% | -4.2% |
| Q1 2019 | $513,000 | +23.3% | 6,315 | 0.0% | 0.61% | +13.9% |
| Q4 2018 | $416,000 | – | 6,315 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |